Cutting-edge medical treatments like gene therapy and cancer diagnostics require access to many separately patented genes, each owned by a small biotech startup that demands a price reflecting potential profits from the whole therapy, creating a holdup problem where assembling all the patents becomes prohibitively costly.

causalpending

Speaker

Michael Heller

Evidence Quote

“unless you can assemble get agreement from every single patent owner in the room the tool or the therapy doesn't work”

Source

Michael Heller on Gridlock and the Tragedy of the Anticommons 11/02/2009— EconTalk
Created: 6/16/2026, 2:51:25 PM

Your notes

Loading notes...